Cytek Biosciences, Inc. income statement CTKB

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Cytek Biosciences, Inc. reported revenue of $201.5 million, up 0.5% from the year before. It recorded a net loss of $66.5 million. The operating loss came to $40.4 million, an operating margin of -20.0%. Over the twelve months ended Sep 30, 2026, revenue was $207.6 million. Across the 5 fiscal years shown, revenue grew from $128.0 million in fiscal 2021 to $201.5 million in fiscal 2025, about 12.0% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021
Revenue	208 +5.5%	201 +0.5%	200 +3.9%	193 +17.7%	164 +28.2%	128
Cost of revenue	94 +2.6%	97 +8.6%	89 +6.9%	84 +32.6%	63 +29.2%	49
Gross profit	114 +8.0%	104 -6.0%	111 +1.5%	109 +8.4%	101 +27.6%	79
Research and development	38 +1.2%	36 -7.4%	39 -10.8%	44 +26.7%	35 +42.6%	24
Selling, general and administrative	120 +20.1%	108 +17.5%	92 -1.0%	93 +37.1%	68 +49.1%	46
Operating expenses	158 +15.0%	145 +10.0%	132 -4.1%	137 +33.6%	103 +46.9%	70
Operating income	-44 -38.0%	-40 -96.8%	-21 +26.3%	-28 -1443.5%	-2 -119.7%	9
Interest income	3 +25.9%	2 -56.7%	5 -20.1%	6 +38.8%	5 +9326.5%	0
Interest expense	0 +101.6%	0 +109.0%	-5	—	—	—
Other non-operating income (expense)	1 -91.2%	9 +97.2%	4 -42.7%	8 +665.6%	1 +166.7%	-2
Pretax income	—	-30 -423.5%	-6 +63.7%	-16 -1346.7%	1 -78.8%	6
Income tax	41 +1646.4%	37 +11368.1%	0 +109.0%	-4 -190.9%	-1 -142.0%	3
Net income	—	-67 -1005.3%	-6 +50.4%	-12 -589.0%	2 -17.9%	3
Basic EPS	-0.63 -527.5%	—	—	-0.09 -550.0%	0.02	0.00
Diluted EPS	-0.63 -527.5%	—	—	-0.09 -550.0%	0.02	0.00
Weighted average shares, basic	129 +0.9%	128 -2.2%	131 -3.5%	135 +0.6%	135 +75.3%	77
Weighted average shares, diluted	129 +0.9%	128 -2.2%	131 -3.5%	135 -2.4%	139 +69.9%	82
Other measures
Depreciation and amortization	8 +4.6%	8 +5.1%	7 +19.2%	6 +142.7%	2 +100.6%	1
EBITDA	-36 -48.3%	-33 -146.5%	-13 +38.9%	-22 -3268.2%	1 -93.4%	10
Interest coverage	-562.56x	-85.20x	—	—	—	—
Margins
Gross margin	54.75%	51.84%	55.43%	56.69%	61.56%	61.86%
Operating margin	-21.13%	-20.04%	-10.24%	-14.43%	-1.10%	7.16%
Pretax margin	—	-14.81%	-2.84%	-8.14%	0.77%	4.64%
Profit margin	—	-33.02%	-3.00%	-6.29%	1.51%	2.37%
EBITDA margin	-17.34%	-16.28%	-6.64%	-11.29%	0.42%	8.13%
Effective tax rate	—	—	—	—	-97.14%	49.02%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Laboratory Analytical Instruments (SIC 3826)
Listed as: CTKB (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Fremont, CA
SEC filer status: Accelerated filer
SEC CIK: 1831915

Other Laboratory Analytical Instruments companies

All 25 Laboratory Analytical Instruments companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.